Cialis: first PDE5 inhibitor licensed for benign prostatic hyperplasia

Tadalafil (Cialis) has been approved for the treatment of benign prostatic hyperplasia (BPH).

Tadalafil (Cialis) provides a new treatment option for the management of benign prostatic hyperplasia | SCIENCE PHOTO LIBRARY
Tadalafil (Cialis) provides a new treatment option for the management of benign prostatic hyperplasia | SCIENCE PHOTO LIBRARY

The phosphodiesterase 5 inhibitor is thought to relieve BPH symptoms by relaxing smooth muscle and increasing blood flow to the bladder, prostate and urethra.

Efficacious from as early as week one

The efficacy and safety of tadalafil in BPH was displayed in four 12-week clinical studies that enrolled over 1,500 men. In each study, treatment with tadalafil 5mg daily improved total International Prostate Symptom score by around two points more than placebo, with improvements being observed as early as week one.

Suitable for BPH with erectile dysfunction

Cialis can be used in patients with BPH who require treatment for erectile dysfunction (ED) as the 5mg once-daily dose is licensed for both indications, provided the patient requires frequent use in ED (at least twice weekly).

View Cialis drug record
 
Further information: Lilly Eli & Co Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Direct-acting oral anticoagulants set for wider use under NHS deal

Direct-acting oral anticoagulants set for wider use under NHS deal

More than half a million more people will be able to...

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...